BIB vs. AMGN
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and Amgen Inc. (AMGN).
BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIB or AMGN.
Correlation
The correlation between BIB and AMGN is 0.65, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BIB vs. AMGN - Performance Comparison
Key characteristics
BIB:
-0.05
AMGN:
-0.12
BIB:
0.18
AMGN:
0.00
BIB:
1.02
AMGN:
1.00
BIB:
-0.03
AMGN:
-0.14
BIB:
-0.17
AMGN:
-0.35
BIB:
9.68%
AMGN:
9.20%
BIB:
36.05%
AMGN:
25.86%
BIB:
-67.24%
AMGN:
-78.04%
BIB:
-53.61%
AMGN:
-22.68%
Returns By Period
In the year-to-date period, BIB achieves a -9.45% return, which is significantly lower than AMGN's -7.44% return. Over the past 10 years, BIB has underperformed AMGN with an annualized return of -2.83%, while AMGN has yielded a comparatively higher 7.31% annualized return.
BIB
-9.45%
-3.97%
-8.98%
-4.69%
-3.93%
-2.83%
AMGN
-7.44%
-7.17%
-14.16%
-4.25%
4.42%
7.31%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BIB vs. AMGN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Amgen Inc. (AMGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIB vs. AMGN - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.97%, less than AMGN's 3.48% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.89% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
AMGN Amgen Inc. | 3.48% | 2.96% | 2.95% | 3.13% | 2.78% | 2.41% | 2.71% | 2.65% | 2.74% | 1.95% | 1.53% | 1.65% |
Drawdowns
BIB vs. AMGN - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum AMGN drawdown of -78.04%. Use the drawdown chart below to compare losses from any high point for BIB and AMGN. For additional features, visit the drawdowns tool.
Volatility
BIB vs. AMGN - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 11.78% compared to Amgen Inc. (AMGN) at 7.57%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than AMGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.